Kuros Biosciences
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 25, Schlieren, Zurich, 8952,...Phone Number
+41 447334747Website
www.kurosbio.comRevenue
$37.7 MillionStock Symbol
KURNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kuros Biosciences
Kuros Biosciences is a Swiss-headquartered global innovation company focused on developing and delivering advanced biologic technologies for bone healing, particularly through their MagnetOs bone graft products. Their offerings include a range of solutions for spine and extremities, designed to enhance patient recovery and address unmet clinical needs. The company prioritizes high-quality, evidence-based data to support surgeons in making informed product choices. With a strong commitment to research and clinical evidence, Kuros aims to improve the quality of life for patients undergoing surgical procedures.Explore more
Kuros Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kuros Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kuros Biosciences
Funding: Get notified immidiatlly once Kuros Biosciences has new funding data
Kuros Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Kuros Biosciences recently announced quarterly report
Check out if Kuros Biosciences is spiking on competitors!
Check if Kuros Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Kuros Biosciences had a recent Job posting/layoffs
Product Launch: Get notified when Kuros Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Kuros Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kuros Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kuros Biosciences.
Kuros Biosciences financials insights
Gather financial insights about Kuros Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2005
Private Equity
$5.8M
2015
Private Equity
$20.7M
2018
Stock Offering
$16.7M
2019
Debt
$5.2M
Stock Offering
$12.9M
Kuros Biosciences Tech Stack
A closer look at the technologies used by Kuros Biosciences
Most Recent Scoops
Project
expensed approximately CHF 2 million in business transformation costs in H1 2026, primarily related to product engineers, operators, IT experts, and selected IT applications, as part of a deliberate investment to strengthen system infrastructure through automation, digitization, and a global MRP backbone to support scalable growth.
Spending/Investment, Business Finance, Corporate Strategy, Finance
Earnings
reported CHF 9.7 million in cash and CHF 44.4 million in receivables as of the end of June 2026, totaling CHF 54.2 million in combined cash and receivables, while remaining debt-free with an undrawn CHF 12.4 million bridge facility available.
Accounting, Financial Reporting, Finance, Financing & Debt
Earnings
provided a financial outlook projecting revenue growth of approximately 35% for 2026 and expects revenue to more than double from CHF 146 million in 2025 to between CHF 300 million and CHF 330 million by 2028, targeting an adjusted EBITDA margin above 20% by 2028 through unit cost optimization, commercial operating leverage, targeted R&D investments, and G&A operational leverage.
Earnings, Research & Development, Forecasting, Finance, Financial Operations
Product Launch
Product Development, Product Launch
Kuros Biosciences News & Media
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
Ad-hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
Kuros Biosciences AG (CSBTF) Analyst/Investor Day June 17, 2026 3:00 AM EDTCompany ParticipantsCarly DummerChristopher Fair - CEO & DirectorJoost de...Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in ZürichKuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kuros Biosciences
Sign Up For FreeTo access detailed company insights
Kuros Biosciences is a Swiss-headquartered global innovation company focused on developing and delivering advanced biologic technologies for bone healing, particularly through their MagnetOs bone graft products. Their offerings include a range of solutions for spine and extremities, designed to enhance patient recovery and address unmet clinical ne... Read More
